Literature DB >> 23689725

Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Erlina Burhan1, Carolien Ruesen, Rovina Ruslami, Arum Ginanjar, Hadiarto Mangunnegoro, Purwantyastuti Ascobat, Rogier Donders, Reinout van Crevel, Rob Aarnoutse.   

Abstract

Numerous studies have reported low concentrations of antituberculosis drugs in tuberculosis (TB) patients, but few studies have examined whether low drug concentrations affect TB treatment response. We examined steady-state plasma concentrations of isoniazid, rifampin, and pyrazinamide at 2 h after the administration of drugs (C(2 h)) among 181 patients with pulmonary tuberculosis in Indonesia and related these to bacteriological response during treatment. C(2 h) values below reference values for either isoniazid, rifampin, or pyrazinamide were found in 91% of patients; 60% had at least two low C(2 h) concentrations. The isoniazid C2 h was noticeably lower in fast versus slow acetylators (0.9 mg/liter versus 2.2 mg/liter, P < 0.001). At the end of treatment, 82% of the patients were cured, whereas 30 patients (17%) had dropped out during the study, and 2 patients (1%) failed treatment. No association was found between C(2 h) concentrations and sputum culture results at 8 weeks of treatment. Post hoc analysis showed that patients with low pyrazinamide C2 h (P = 0.01) and patients with large extensive lung lesions (P = 0.01) were at risk of at least one positive culture at week 4, 8, or 24/32. Antituberculosis drug concentrations were often low, but treatment response was nevertheless good. No association was found between drug concentrations and 8 weeks culture conversion, but low pyrazinamide drug concentrations may be associated with a less favorable bacteriological response. The use of higher doses of pyrazinamide may warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689725      PMCID: PMC3719785          DOI: 10.1128/AAC.02468-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Therapeutic drug monitoring in the treatment of active tuberculosis.

Authors:  Aylin Babalik; Aylin Babalik; Sharyn Mannix; Denis Francis; Dick Menzies
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

2.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

3.  Biomarkers for tuberculosis disease activity, cure, and relapse.

Authors:  Patrick Peter John Phillips; Geraint R Davies; Denis A Mitchison
Journal:  Lancet Infect Dis       Date:  2010-02       Impact factor: 25.071

4.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

6.  Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.

Authors:  Helen McIlleron; Roxana Rustomjee; Mahnaz Vahedi; Thuli Mthiyane; Paolo Denti; Catherine Connolly; Wasima Rida; Alexander Pym; Peter J Smith; Philip C Onyebujoh
Journal:  Antimicrob Agents Chemother       Date:  2012-03-12       Impact factor: 5.191

7.  Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

Authors:  Shashikant Srivastava; Jotam G Pasipanodya; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2011-10-21       Impact factor: 5.226

8.  Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.

Authors:  David P Holland; Carol D Hamilton; Amy C Weintrob; John J Engemann; Ellen R Fortenberry; Charles A Peloquin; Jason E Stout
Journal:  Pharmacotherapy       Date:  2009-05       Impact factor: 4.705

9.  Peak plasma rifampicin level in tuberculosis patients with slow culture conversion.

Authors:  K-C Chang; C-C Leung; W-W Yew; K-M Kam; C-W Yip; C-H Ma; C-M Tam; E C-C Leung; W-S Law; W-M Leung
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-24       Impact factor: 3.267

10.  Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.

Authors:  Rovina Ruslami; Hanneke M J Nijland; I Gusti N Adhiarta; Sri H K S Kariadi; Bachti Alisjahbana; Rob E Aarnoutse; Reinout van Crevel
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

View more
  39 in total

1.  Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.

Authors:  Abdullah Alsultan; Guohua An; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Authors:  Hongmei Yang; Anthony Enimil; Fizza S Gillani; Sampson Antwi; Albert Dompreh; Antoinette Ortsin; Eugene Adu Awhireng; Maxwell Owusu; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

3.  Reply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response".

Authors:  Rob Aarnoutse; Carolien Ruesen; Erlina Burhan; Reinout van Crevel; Rovina Ruslami
Journal:  Antimicrob Agents Chemother       Date:  2014       Impact factor: 5.191

4.  Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response.

Authors:  Onno W Akkerman; Richard van Altena; Mathieu S Bolhuis; Tjip S van der Werf; Jan-Willem Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2014       Impact factor: 5.191

5.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

6.  Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.

Authors:  Stellah G Mpagama; Norah Ndusilo; Suzanne Stroup; Happiness Kumburu; Charles A Peloquin; Jean Gratz; Eric R Houpt; Gibson S Kibiki; Scott K Heysell
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

Review 7.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 8.  Pharmacologic considerations in use and development of antituberculosis drugs.

Authors:  Geraint Davies
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-18       Impact factor: 6.915

9.  Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.

Authors:  Christine Sekaggya-Wiltshire; Amrei von Braun; Mohammed Lamorde; Bruno Ledergerber; Allan Buzibye; Lars Henning; Joseph Musaazi; Ursula Gutteck; Paolo Denti; Miné de Kock; Alexander Jetter; Pauline Byakika-Kibwika; Nadia Eberhard; Joshua Matovu; Moses Joloba; Daniel Muller; Yukari C Manabe; Moses R Kamya; Natascia Corti; Andrew Kambugu; Barbara Castelnuovo; Jan S Fehr
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

10.  Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; P K Bhavani; T Kannan; S Ramesh Kumar; N Poorana Gangadevi; V V Banurekha; L Sekar; N Ravichandran; G Mathevan; G N Sanjeeva; Rajeshwar Dayal; Soumya Swaminathan
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.